Details:
Ac-225, a core material used for TAT, a new therapeutic concept to attack cancer cells in body, applying a therapeutic agent in which alpha particle-emitting radionuclides that can kill cancer cells are bound to antibodies selectively accumulated in protein in cancer cells.
Lead Product(s): Actinium-225 PET
Therapeutic Area: Oncology Product Name: Ac-225
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Cyclotron
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
Strategic research collaboration aims at to evaluating the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.
Lead Product(s): DS-1062,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 29, 2020
Details:
Under the terms of the agreement, Merck, Taiho and Astex will combine preclinical candidates and their data with knowledge and expertise from their respective research programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $2,550.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration January 06, 2020